Logo image of AUTL

AUTOLUS THERAPEUTICS PLC (AUTL) Stock Overview

NASDAQ:AUTL - US05280R1005 - ADR

1.6 USD
-0.01 (-0.62%)
Last: 8/27/2025, 11:03:51 AM

AUTL Key Statistics, Chart & Performance

Key Statistics
52 Week High5
52 Week Low1.11
Market Cap425.83M
Shares266.14M
Float213.38M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.85
PEN/A
Fwd PEN/A
Earnings (Next)11-10 2025-11-10/bmo
IPO06-22 2018-06-22
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


AUTL short term performance overview.The bars show the price performance of AUTL in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30

AUTL long term performance overview.The bars show the price performance of AUTL in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40 -50

The current stock price of AUTL is 1.6 USD. In the past month the price decreased by -33.47%. In the past year, price decreased by -59.03%.

AUTOLUS THERAPEUTICS PLC / AUTL Daily stock chart

AUTL Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.75 369.42B
AMGN AMGEN INC 13.18 154.80B
GILD GILEAD SCIENCES INC 14.78 141.90B
VRTX VERTEX PHARMACEUTICALS INC 22.96 99.70B
REGN REGENERON PHARMACEUTICALS 12.87 62.25B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 59.25B
ARGX ARGENX SE - ADR 76.17 43.22B
ONC BEONE MEDICINES LTD-ADR 6.07 35.72B
INSM INSMED INC N/A 28.08B
BNTX BIONTECH SE-ADR N/A 24.64B
NTRA NATERA INC N/A 22.58B
BIIB BIOGEN INC 8.51 19.97B

About AUTL

Company Profile

AUTL logo image Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. The company is focused on chimeric antigen receptor (CAR)-T cell therapy. Using a suite of proprietary and modular T cell programming technologies, it is engineering targeted, controlled and highly active T cell therapy product candidates that are designed to recognize target cells, break down their defense mechanisms and eliminate these cells. The company has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. Its products pipeline includes obe-cel (FELIX), obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting T Cell Receptor Beta Constant (TRBC) 1 and TRBC 2.

Company Info

AUTOLUS THERAPEUTICS PLC

The Mediaworks, 191 Wood Lane

London W12 7RZ GB

CEO: Christian Itin

Employees: 649

AUTL Company Website

AUTL Investor Relations

Phone: 442038296230

AUTOLUS THERAPEUTICS PLC / AUTL FAQ

What is the stock price of AUTOLUS THERAPEUTICS PLC today?

The current stock price of AUTL is 1.6 USD. The price decreased by -0.62% in the last trading session.


What is the ticker symbol for AUTOLUS THERAPEUTICS PLC stock?

The exchange symbol of AUTOLUS THERAPEUTICS PLC is AUTL and it is listed on the Nasdaq exchange.


On which exchange is AUTL stock listed?

AUTL stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for AUTOLUS THERAPEUTICS PLC stock?

17 analysts have analysed AUTL and the average price target is 9.65 USD. This implies a price increase of 503.08% is expected in the next year compared to the current price of 1.6. Check the AUTOLUS THERAPEUTICS PLC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is AUTOLUS THERAPEUTICS PLC worth?

AUTOLUS THERAPEUTICS PLC (AUTL) has a market capitalization of 425.83M USD. This makes AUTL a Small Cap stock.


How many employees does AUTOLUS THERAPEUTICS PLC have?

AUTOLUS THERAPEUTICS PLC (AUTL) currently has 649 employees.


What are the support and resistance levels for AUTOLUS THERAPEUTICS PLC (AUTL) stock?

AUTOLUS THERAPEUTICS PLC (AUTL) has a support level at 1.6 and a resistance level at 2.23. Check the full technical report for a detailed analysis of AUTL support and resistance levels.


Is AUTOLUS THERAPEUTICS PLC (AUTL) expected to grow?

The Revenue of AUTOLUS THERAPEUTICS PLC (AUTL) is expected to grow by 475.44% in the next year. Check the estimates tab for more information on the AUTL EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy AUTOLUS THERAPEUTICS PLC (AUTL) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does AUTOLUS THERAPEUTICS PLC (AUTL) stock pay dividends?

AUTL does not pay a dividend.


When does AUTOLUS THERAPEUTICS PLC (AUTL) report earnings?

AUTOLUS THERAPEUTICS PLC (AUTL) will report earnings on 2025-11-10, before the market open.


What is the Price/Earnings (PE) ratio of AUTOLUS THERAPEUTICS PLC (AUTL)?

AUTOLUS THERAPEUTICS PLC (AUTL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.85).


What is the Short Interest ratio of AUTOLUS THERAPEUTICS PLC (AUTL) stock?

The outstanding short interest for AUTOLUS THERAPEUTICS PLC (AUTL) is 6.63% of its float. Check the ownership tab for more information on the AUTL short interest.


AUTL Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

AUTL Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to AUTL. While AUTL seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

AUTL Financial Highlights

Over the last trailing twelve months AUTL reported a non-GAAP Earnings per Share(EPS) of -0.85. The EPS increased by 27.35% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -31.59%
ROE -65.74%
Debt/Equity 0.71
Chartmill High Growth Momentum
EPS Q2Q%18.18%
Sales Q2Q%N/A
EPS 1Y (TTM)27.35%
Revenue 1Y (TTM)496%

AUTL Forecast & Estimates

17 analysts have analysed AUTL and the average price target is 9.65 USD. This implies a price increase of 503.08% is expected in the next year compared to the current price of 1.6.

For the next year, analysts expect an EPS growth of -0.83% and a revenue growth 475.44% for AUTL


Analysts
Analysts85.88
Price Target9.65 (503.13%)
EPS Next Y-0.83%
Revenue Next Year475.44%

AUTL Ownership

Ownership
Inst Owners89.31%
Ins Owners0.01%
Short Float %6.63%
Short Ratio6.53